Objective: to study the pyramidal tract in patients with highly active multiple sclerosis (HAMS) during treatment switching from first-line MS therapy to second-line therapy due to suboptimal response.Material and methods. 24 patients with HAMS were analyzed. Depending on the severity of pyramidal functional system (PFS) impairment according to EDSS, patients were divided into 2 groups; group 1 — 17 patients with an EDSS score of 0—2.5 points, group 2 — 7 patients with an EDSS score of ≥3 points. All patients underwent MRI of the brain according to the standard protocol. The diffusion tensor images (DTI) were processed using the DTI FiberTrak software.Results. The volume of the pyramidal tract was decreased in patients in group 2 (p<0.001), asymmetry of the indicator was noted, in several patients a decrease in volume on the clinically intact side, which may indicate visually undetectable signs of damage of pyramidal tract. There was a clear tendency for a decrease in fractional anisotropy and a decrease in pyramidal tract length with increasing pyramidal deficit (p<0.001). Negative correlations were found between indicators of neurological deficit and pyramidal tract volume and length (Spearman's Rho=-0.5246; p<0.001) and a direct correlation between duration of MS and apparent diffusion coefficient (ADC) and inversely — with fractional anisotropy (Pearson's R=-0.290; p=0.039).Conclusion. The observed decrease in pyramidal tract volume and length, increase in ADC, asymmetry of these indicators, correlations with the degree of pyramidal insufficiency, EDSS and duration of MS can obviously serve as additional criteria for evaluation of disease dynamics and efficacy of therapy.
8 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To study the effect of highly effective multiple sclerosis disease-modifying drugs (ocrelizumab and cladribine) on the course of the disease using diffusion-weighted MRI with tractography. Materials and methods. The study included 23 patients divided into two groups: Group 1 received cladribine, and Group 2 received ocrelizumab. To assess the severity of damage to the pyramidal tract and the effectiveness of treatment, all patients underwent dynamic brain MRI with tractography before the start of therapy (baseline) and one year after the start of treatment. Results. The comparison of the results of the examination of the participants of group 1 with the indicators of the control group did not show significant differences in the volume of the pyramidal tract, FA, and ADC. Analysis of results one year after starting ocrelizumab treatment showed a statistically significant increase in ADC, while other parameters showed no significant change. Conclusion. The comparison of the examination results of group 1 patients with those in the control group showed a decrease in the length of the pyramidal tract. However, there was no difference between the values before and after treatment. These results suggest that cladribine therapy contributes to slowing down neurodegenerative processes. Analysis of the results one year after the start of treatment with ocrelizumab showed a slight negative trend, indicating the progression of neurodegenerative processes. The observed results are probably due to more severe baseline impairment of the pyramidal function and ambulation in this group of patients compared to group 1.
19 October 2024 in Neurology, Neuropsychiatry, Psychosomatics
Cladribine has a well-defined activity against lymphocytes, leading to their selective depletion.Objective: to determine the efficacy and safety of cladribine in the treatment of multiple sclerosis (MS) in real-world clinical practice.Material and methods. The study involved 82 patients (57 women and 25 men, mean age 36.4±9.3 years) with a disease duration of 2.2±1.5 years. Seven (9%) patients had secondary progressive MS (SPMS), 6 (7%) had rapidly progressive MS (RPMS) and 69 (84%) had highly active MS (HAMS). According to the instructions for use, oral therapy with cladribine was administered in two short courses (up to 10 days per year) to achieve a long-term effect on the immune system. The dose of cladribine was calculated based on the body weight.Results. The average frequency of exacerbations per year before starting therapy was 1.6, while it decreased to 0.2 during cladribine therapy. An exacerbation was observed in 18 patients (22%) at the end of the first course of cladribine treatment and in one patient (2.6%) after the second treatment course. Thus, the number of exacerbations decreased by 78% after the first year of treatment and by 97.4% after the second year of treatment. The mean EDSS score was 3.2±2.5 points before the start of treatment, 3.6±2.5 points after the first course of treatment and 3.4±2.5 points after the second course (p>0.05). MRI results showed a decrease in disease activity by 83% after the first course of cladribine therapy and by 97.4% after the second course. No serious adverse events occurred in any of the patients.Conclusion. We demonstrated efficacy and safety of cladribine in real-life clinical practice in MS patients with frequent exacerbations and rapid disability progression (SPMS, RPMS, HAMS).
4 November 2025 in Siberian Scientific Medical Journal
The gut microbiota represents a complex regulatory ecosystem that influences metabolism, immune responses, and neurovegetative functions. Alterations in its composition may contribute to chronic inflammation and the activation of autoimmune processes, suggesting a potential role of intestinal dysbiosis in the pathogenesis of multiple sclerosis (MS). Aim of the study was to investigate the microbial and endotoxin profiles in healthy individuals and patients with relapsing-remitting MS (RRMS), both treatment-naive and receiving disease-modifying therapies (DMTs). Material and methods . The study included 42 participants divided into three independent groups: healthy controls, untreated RRMS patients (RRMS-Naive), and RRMS patients receiving DMTs (RRMS-DMT). To assess the levels of 57 microbial markers (49 bacterial, 4 fungal, 3 viral) and endotoxin, gas chromatography-mass spectrometry (GC-MS) of microbial markers was used. Results. Patients receiving DMTs showed reduced levels of endotoxin and several bacterial markers compared to both the control and untreated groups. The most significant differences were observed between the RRMS-DMT and RRMS-Naive groups. Statistically significant differences were identified in markers such as Clostridium propionicum, Bacteroides fragilis, Prevotella spp., Streptococcus spp., Clostridium hystolyticum, among others. Conclusions. The findings indicate an association between the clinical status of RRMS patients and the levels of microbial and endotoxin markers. GC-MS profiling of microbial markers may serve as an additional tool for evaluating systemic inflammation and therapeutic response.
23 August 2025 in Neurology, Neuropsychiatry, Psychosomatics
The combination of polyethylene glycol with interferon beta-1a has expanded the therapeutic possibilities for treating multiple sclerosis (MS). By prolonging the half-life of interferon beta-1a and increasing its effect, this new formula provides safe and effective first-line therapy with reduced frequency of administration.Objective: to investigate the safety and efficacy of intramuscular sampeginterferon beta-1a (SPI) in patients with relapsing-remitting MS, as well as factors influencing discontinuation of treatment.Material and methods. Data from 14 patients with relapsing-remitting MS with mild activity who received SPI therapy at the Moscow Region Multiple Sclerosis Centre between June 2024 and May 2025 were analysed.Results. During the year prior to the appointment of SPI, exacerbations of MS were observed in almost half (40%) of patients; during the period of SPI therapy (1 year), there were no exacerbations. The positive effect of SPI was confirmed by brain neuroimaging data and the absence of an increase in neurological deficit on the EDSS scale throughout the observation period. All recorded adverse reactions were of first or second degree severity and did not require discontinuation of SPI. A distinctive feature of SPI use was a significant reduction in the frequency of local reactions, which contributed to increased patient adherence to the therapy.Conclusion. Preliminary analysis results demonstrate the efficacy and safety of SPI therapy in patients with relapsing-remitting MS. Infrequent injections of the drug contribute to increased patient adherence to pathogenetic treatment and improved quality of life.
4 August 2025 in Russian Journal of Child Neurology
Balo’s concentric sclerosis (BCS) is a rare demyelinating disorder. The article analyzes six BCS cases diagnosed using magnetic resonance imaging, clinical data, and cerebrospinal fluid studies. The goal is to differentiate BCS from multiple sclerosis (MS), assess prognosis, and evaluate therapy. Patients exhibited concentric demyelination lesions. In two cases, oligoclonal antibodies were absent (type 1, typical for BCS), while others showed type 2 (more common in MS). Treatment included corticosteroids, plasmapheresis, and anti-B-cell therapy. Disease course varied: some patients had a monophasic course, while others experienced relapsing symptoms resembling pseudotumoral MS. Magnetic resonance imaging showed lesion reduction, but some patients retained neurological deficits.BCS may be a distinct nosological entity but requires careful differentiation from MS. Early imaging and cerebrospinal fluid analysis are crucial for diagnosis. MS-like therapy is effective, but further research is needed.